Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

The requested reference [d79a8f4e0c9722383c3ad1f1de780d57b3bf961c] no longer exists in our database. It has been replaced by the current reference: [05e637eb8ec52afbd8d45ac5ce1ea81db7d01f23]

Authors
Category Systematic review
JournalJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 0add62ab589f865ab85eec558158df2c978844ec
First added on: Feb 08, 2025